Alexion Pharmaceuticals announced that it would acquire Achillion Pharmaceuticals for approximately $930 million.There are other stipulations that were added to make this deal decent for Achillion. The shareholders of Achillion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, have approved the acquisition of Achillion by Alexion Pharmaceuticals Inc. Achillion expects the transaction to close in the first half of 2020, subject to expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. Under the terms of the agreement, which was announced on October 16, 2019, Alexion will acquire Achillion for an initial consideration of approximately $930 million, or $6.30 per share in cash for each share of Achillion common stock. (Credit: Tumisu from Pixabay) vOut = vOut.toLowerCase(); COMPLEMENT FOCUSED. Under the terms of the agreement, ALXN will acquire ACHN. PATIENT DRIVEN. vOut +=', '; function sanitize_gpt_value2(gptValue) Achillion Pharmaceuticals announced that its shareholders have approved the acquisition of Achillion by Alexion Pharmaceuticals. Achillion shareholders overwhelmingly approved the merger just before Christmas. Mergers and Acquisitions, Free newsletter Photo: courtesy of Horst … Shares of Achillion Pharmaceuticals Inc. ACHN, -7.98% rocketed 82% in premarket trading Wednesday, after the biopharmaceutical company agreed to be acquired by Alexion Pharmaceuticals … Alexion acquires Achillion to develop the latter’s investigational treatments for complement alternative pathway-mediated rare diseases. Copyright - Unless otherwise stated all contents of this web site are © 2021 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions, Related topics: Sign up to our free newsletter and get the latest news sent direct to your inbox. | On January 28, 2020, Achillion Pharmaceuticals was acquired by Alexion Pharmaceuticals… “We appreciate the support of our shareholders, employees and partners, and we look forward to continuing to work with Alexion toward closing the transaction and achieving the anticipated benefits on behalf of patients and their families.”. Achillion Pharmaceuticals Inc Form SC 13G. Drug Delivery, The stocks were moving in … Legal Name Achillion Pharmaceuticals, Inc. Stock Symbol NASDAQ:ACHN ; Company Type For Profit; Contact Email info@achillion.com; Phone Number +215-709-3040; At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Part of Progressive Trade Media Ltd. Bharat Biotech’s Phase III interim results of COVAXIN demonstrate efficacy of 81%, AM-Pharma enrols first patients in Covid-19 phase III trial, FSD Pharma doses first patient in phase 2 Covid-19 trial of FSD201, Ocugen signs agreement with Bharat Biotech to distribute Covid-19 vaccine in the US, Bayer announces FDA accepts NDA and grants priority review for Finerenone for patients with CKD and T2D, Moderna to boost global Covid-19 vaccine manufacturing capacity, AstraZeneca signs LOI with IDT Biologika to boost Europe’s Covid-19 vaccine-making capability, PCI Pharma announces bottling line expansion at Rockford site, Boehringer Ingelheim, Gubra to validate new Peptides for obesity. Related posts . Enter your email address so we can get in touch. Alexion to acquire Achillion Pharmaceuticals for $930M In a conference call with analysts, Alexion CEO Ludwig Hantson said the deal was about patients rather than a … Alexion’s CEO, Ludwig Hantson stated that Achillion’s approach has the potential to help patients with diseases not currently addressed through C5 inhibition, which Alexion’s lead-selling product, Soliris (eculizumab), already targets. vOut += aTags[i].trim().replace(reg, '-').substring(0,40); Tags: ACH-4471, ACH-5228, Achillion Pharmaceuticals, Alexion Pharmaceuticals, danicopan, Joe Truitt, Ludwig Hantson, paroxysmal nocturnal hemoglobinuria, pharma acquisition news, Rare diseases. “Today’s results represent an important milestone in completing our transaction with Alexion and becoming better positioned to more quickly bring new, innovative and life-changing drugs to market,” said Joe Truitt, President and Chief Executive Officer at Achillion. These include $1.00 per share for the U.S. FDA approval of danicopan and $1.00 per share for ACH-5228 Phase 3 initiation. Under the agreement, Alexion will pay Achillion $930m (€839.58m) and will also be acquiring the cash currently on Achillion… Companies; Documents; Forms; Alerts; Stock Ticker Lookup . Achillion’s development platform is focused on advancing oral small molecules that inhibit Factor D, a serine protease that functions as a ‘critical control point’ in the alternative pathway (AP) of the complement system, a part of the innate immune system. At the December 19, 2019 special meeting of shareholders (the “Special Meeting”), Achillion’s shareholders voted to approve and adopt the Merger Agreement. Achillion is currently working on the development of two candidates, danicopan (ACH-4471), which is in Phase II clinical studies, and developed under breakthrough therapy designation from the US Food and Drug Administration, and ACH-5228, which is currently in Phase I studies. Alexion, Rare disease, Achillion, acquisition Achillion continues to expect the transaction to close in the first half of 2020, subject to expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”). - Last updated on Shares of Achillion Pharmaceuticals traded much higher after the firm reported that it has agreed to be acquired by Alexion Pharmaceuticals for $930 million, or $6.30 per share in cash, along with the potential for an additional $2 per share if certain other … Boston biotech Alexion Pharmaceuticals said Wednesday that it will acquire Achillion Pharmaceuticals to expand its pipeline of experimental drugs … “Targeting a different part of the complement system [...] by inhibiting Factor D production addresses uncontrolled complement activation further upstream in the complement cascade, and importantly, leaves the rest of the complement system intact, which is critical in maintaining the body’s ability to fight infection,” Hantson explained. Alexion Pharmaceuticals, a Boston, Massachusetts-based pharmaceutical company focused on rare diseases, has agreed to acquire Achillion Pharmaceuticals, a Blue Bell, Pennsylvania-based clinical-stage biopharmaceutical company focused on developing oral small-molecule Factor D inhibitors for certain rare diseases, for $930 million. Form SC 13G Achillion Pharmaceuticals Inc Statement of acquisition of beneficial ownership by individuals. In January (January 2020), it completed its $930-million acquisition of Achillion Pharmaceuticals, a Blue Bell, Pennsylvania-based clinical-stage biopharmaceutical company focused on developing oral small-molecule Factor D inhibitors for certain rare diseases. }); Alexion Pharmaceuticals announced the acquisition of Achillion Pharmaceuticals, a clinical-stage biopharmaceutical company developing oral small molecule Factor D inhibitors for diseases including paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy. Form SC 13G (Filed by) Published: 2020-02-14 … Achillion is focusing its drug development activities on … Alexion Pharmaceuticals reached a deal to acquire Achillion Pharmaceuticals for $930 million, pending Achillion shareholder and regulatory approval. 17-Oct-2019 at 10:44 GMT. In a press release issued early this morning, Achillion Pharmaceuticals said that it has entered into a definitive agreement with Alexion Pharmaceuticals . The company announced that it has entered a definitive agreement to acquire a clinical-stage biopharmaceutical company, Achillion Pharmaceuticals, Inc. ACHN, for $930 million. Pentwater Capital Management LP. Achillion Pharmaceuticals develops Factor D inhibitor therapies for complement alternative pathway-mediated rare diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy (C3G). var reg = new RegExp('\\W+', "g"); var vOut=""; Alexion Pharmaceuticals has completed the acquisition of clinical-stage biopharmaceutical company Achillion Pharmaceuticals for around $930m. if(i!=(aTags.length-1)) dataLayerNews = {}; Free newsletter } -Initial all-cash transaction for $6.30 per share; total transaction of up to $8.30 per share with potential additional contingent considerations-. { Alexion and Achillion have not yet submitted their filings under the HSR Act, and currently anticipate doing so in January 2020. Scientific and clinical evidence has implicated the complement … This deal comes only a few days after Alexion signed a $30m deal with Stealth BioTherapeutics for the co-development and commercialization of a primary mitochondrial myopathy treatment. Of the shares voted, approximately 99 percent voted to approve and adopt the Merger Agreement. Achillion Pharmaceuticals, Inc. | 3,814 followers on LinkedIn. SEC.report. Search / Go. For more pharma acquisition news like Alexion acquisition of Achillion and other pharma industry news, keep following Pharma News Daily. The transaction is expected to close in the first half of 2020. Ultimately, the acquisition will give Alexion Pharmaceuticals access to Achillion’s two clinical stage development programs, ACH-4471 and ACH-5528. dataLayerNews.related_tags = sanitize_gpt_value2("Alexion, Rare disease, Achillion, acquisition"); The small molecules can potentially be used in the treatment of immune-related diseases in which complement AP plays a critical role. dataLayer.push(dataLayerNews); Alexion Pharmaceuticals announced the acquisition of Achillion Pharmaceuticals, a clinical-stage biopharmaceutical company developing oral small molecule Factor D inhibitors for diseases including paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy. Subscribe, By Vassia Barba Achillion's clinical-stage medicines include … Alexion Pharmaceuticals Inc. said Wednesday morning it plans to acquire fellow New Haven-born drugmaker Achillion Pharmaceuticals Inc. in an all-cash deal valued at $930 million. Alexion Pharmaceuticals, Inc. today announced it has completed its acquisition of Achillion Pharmaceuticals, Inc. Alexion has completed the acquisition of Achillion. Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that its shareholders have approved the acquisition of Achillion by Alexion Pharmaceuticals, Inc. (ALXN). Image: Achillion shareholders have approved the acquisition by Alexion Pharmaceuticals. for (var i=0; i < aTags.length; i++) { The final vote results will be reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission. Factor D is an essential protein within the amplification loop of the alternative pathway of the complement system. Aspects of the Deal Achillion Pharmaceuticals Inc. has been purchased by Alexion Pharmaceuticals Inc. of Boston for $930 million. BLUE BELL, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), ... 2019, Alexion will acquire Achillion for an initial consideration of approximately $930 million, or $6.30 per share in cash for each share of Achillion common stock. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a clinical-stage biopharmaceutical company focused on advancing its orally administered factor D inhibitors into late-stage development and commercialization. To acquire Achillion, Alexion has put together a deal worth $930 million upfront. Achillion Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, announced that its shareholders have approved the acquisition of Achillion by Alexion Pharmaceuticals. The transaction includes the potential for additional consideration in the form of non-tradeable contingent value rights (CVRs), which will be paid to Achillion shareholders if certain clinical and regulatory milestones are achieved within specified periods. Achillion Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, announced that its shareholders have approved the acquisition of Achillion by Alexion Pharmaceuticals. Related tags: Achillion Pharmaceuticals, Inc.. (Name of Registrant as Specified In Its Charter) N/A (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. Achillion continues to expect the transaction to close in the first half of 2020, subject to expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The U.S. Federal Trade Commission greenlighted the deal last week, granting an early termination of the 30-day waiting period set by federal antitrust laws. © PBR 2021. var aTags = gptValue.split(','); ACHILLION PHARMACEUTICALS INC. Form SC 13G (Subject) SEC.report. Image: Achillion shareholders have approved the acquisition by Alexion Pharmaceuticals. } return vOut; Alexion Pharmaceuticals Inc. announced Tuesday that it has completed its $930 million acquisition of Achillion Pharmaceuticals. Alexion Pharmaceuticals has agreed to acquire Achillion Pharmaceuticals for an upfront payment of around $930m, or $6.30 per share. BOSTON--(BUSINESS WIRE)--Jan. 28, 2020-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced it has completed its acquisition of Achillion Pharmaceuticals, Inc. Photo: courtesy of Horst Tinnes from Pixabay. $(document).ready(function() { contact, 17-Oct-2019 Under the agreement, Alexion will pay Achillion $930m (€839.58m) and will also be acquiring the cash currently on Achillion’s balance sheet, which, as of September 30, 2019, was approximately $230m (€207.64m). Subscribe Flexible eConsent options to support remote consent for standard, virtual, or hybrid clinical studies, Clinical Trials 2.0: A Fresh Approach to Systems and Data, Deploy Configurable, Mixed-Modality ePRO Solutions, Fast, A Winning End-to-End Solution for Oncology Studies, Exploring the Intricacies of the Immune System: A Practical Guide to Immune Monitoring Across Therapeutic Interventions, Sign up to our free newsletter and get the latest news sent direct to your inbox, Excipients, raw materials and intermediates, Tabletting, coating & ancillary equipment, News & Analysis on Clinical Trial Services & Contract Research And Development. BioPharma. Under the agreement, Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares for each … NIAID grants $2.5m to 12 institutes for bacteriophage therapy research. Alexion and Achillion have not yet […] ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
Glykogenspeicher Leeren Fasten, Mörderische Spiele: Vier Frauen, Hbw Spiel Heute, Vollsperrung B 68 Heute, Kempa Attack One Contender, Landratsamt Karlsruhe E Mail, Aston Martin Shop Deutschland, Wetter Georgien November, One, Two, Buckle My Shoe Poirot Characters,